{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:06:38Z","timestamp":1774649198633,"version":"3.50.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Programmed death 1 protein (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are promising cancer immunotherapy. Their dermatologic safety profiles are still poorly understood. The purpose of this article is to evaluate the incidence of selected dermatologic and mucosal adverse effects (AEs) and determine the risk of developing these adverse events associated with PD-1\/PD-L1 inhibitors, compared with chemotherapy or ipilimumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed was searched for eligible studies (up to February 21, 2019). Only phase II and phase III randomized controlled trials (RCTs) compared with chemotherapy or ipilimumab monotherapy were included in this meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total 11,465 patients from 18 clinical trials were included in this meta-analysis. Rash and pruritus were the most frequently reported dermatologic AE, with incidence 11.8% and 12.2% respectively. Compared with patients receiving chemotherapy, PD-1\/PD-L1 inhibitor treated patients had higher risk of developing rash (RR\u200a=\u200a1.84), pruritus (RR\u200a=\u200a3.74) and vitiligo (RR\u200a=\u200a9.54), and also lower risk in developing mucosal inflammation (RR\u200a=\u200a0.26), stomatitis (RR\u200a=\u200a0.26), and alopecia (RR\u200a=\u200a0.03). Additionally, anti-PD1\/PD-L1 drugs had similar risk of developing rash and lower risk of inducing pruritus compared to ipilimumab. In the subgroup analysis, PD-L1 inhibitor demonstrated better safety than PD-1 inhibitor in developing rash, with RR\u200a=\u200a1.38 and RR\u200a=\u200a2.11, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our meta-analysis concluded that anti PD-1\/PD-L1 drugs have different dermatological and mucosal safety profile compared to conventional therapy, and differences of dermatological toxicity between PD-1 and PD-L1 inhibitor warrant further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000015731","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:44:01Z","timestamp":1558003441000},"page":"e15731","source":"Crossref","is-referenced-by-count":28,"title":["Risk of dermatologic and mucosal adverse events associated with PD-1\/PD-L1 inhibitors in cancer patients"],"prefix":"10.1097","volume":"98","author":[{"given":"Wenwei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Queen Mary College of Nanchang University, Nanchang, Jiangxi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuquan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Queen Mary College of Nanchang University, Nanchang, Jiangxi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingrui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong University Affiliated Provincial Hospital, Jinan, Shandong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"R2-20230914","first-page":"52","volume":"276","author":"Ni","year":"2017","journal-title":"New checkpoints in cancer immunotherapy"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R4-20230914","doi-asserted-by":"crossref","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","author":"Sharpe","year":"2017","journal-title":"Immunol Rev"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicitiesoftheanti-PD-1andanti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R15-20230914","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2017","journal-title":"Eur J Cancer"},{"key":"R17-20230914","first-page":"2","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","author":"Baxi","journal-title":"BMJ"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1517\/14740338.2015.1085969","article-title":"Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"14","author":"Omar Abdel-Rahman","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1753465816636557","article-title":"Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"10","author":"Abdel-rahman","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Articles Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study ( KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma ( KEYNOTE-002 ): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20230914","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non\u2013Small-Cell Lung Cancer","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer","volume":"373","author":"Borghaei","year":"2017","journal-title":"N Engl J Med"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2016","journal-title":"N Engl J Med"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment ( CheckMate 037 ): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R34-20230914","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2017","journal-title":"Lancet"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Articles atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer ( POPLAR ): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Chang","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R40-20230914","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"R41-20230914","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"R42-20230914","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"R43-20230914","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"R44-20230914","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The balancing act between cancer immunity and autoimmunity in response to immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"R45-20230914","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R46-20230914","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"R47-20230914","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R48-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"R49-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41422-018-0011-0","article-title":"A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201905170-00103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:22:35Z","timestamp":1694730155000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201905170-00103"}},"subtitle":["A meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000015731","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}